Core Insights - CollPlant Biotechnologies is advancing its photocurable dermal filler into clinical trials following positive results from its non-clinical program, marking a significant milestone in aesthetic medicine [1][3] - The new dermal filler combines hyaluronic acid with a modified form of recombinant human collagen (rhCollagen), providing both immediate and long-lasting aesthetic benefits [2][3] Product Development - The photocurable dermal filler is administered as a viscoelastic gel and is stabilized using a proprietary illumination device, transforming into a semi-solid implant upon light activation [2][3] - CollPlant's non-clinical program included a one-year in vivo study confirming long-term durability and biocompatibility assessments that comply with international standards, establishing a strong foundation for clinical advancement [3] Strategic Partnerships - In 2021, CollPlant entered into a development and global commercialization agreement with Allergan, an AbbVie company, which is a leader in the dermal filler market [5]